

Supporting Information

A Ni-NTA-based Red Fluorescence Probe for Protein Labelling in Live Cells†

Ailun Chao[‡], Nan Jiang[‡], Ya Yang, Hongyan Li and Hongzhe Sun*

Department of Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong, P. R. China.

*Correspondence should be addressed to H.S. (hsun@hku.hk).

Synthesis of Compound 1–7

Compound 1: **1** is synthesized based on a previous report¹ with modifications. In a 100 mL reaction flask, 4-formylbenzoic acid (500 mg, 3.3 mmol), 2,4-dimethylpyrrole (634 mg, 6.7 mmol, 2 molar equiv.) and DCM (dichloromethane, 25 mL) were added. The mixture was stirred for 20 min at room temperature under nitrogen. Trifluoroacetic acid (26 μ L) was added and stirred overnight. To the reaction mixture, chloranil (1.638 g, 6.6 mmol, 2 molar equiv. in 5 mL DCM) was added with continuous stirring. After 4 hrs, trimethylamine (4 mL, 28 mmol, 8.6 molar equiv.) was added and stirred for 30 min. Boron trifluoride (4 mL, 17 mmol, 5 molar equiv.) was added and stirred for another 4 hrs. The mixture was diluted with water (50 mL) and extracted with DCM (6 \times 20 mL). The combined organic phase was dried over anhydrous Na₂SO₄ and filtered. The solvent of the filtrate was removed via vacuum evaporation. The compound was purified by column chromatography with DCM/EA (2/1 v/v) with 0.2% acetic acid to afford **5** (210 mg, 18% yield) as brown solid. ¹H NMR (300 MHz, CDCl₃+0.5%TFA) δ 8.26 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 8.1 Hz, 2H), 6.02 (s, 2H), 2.55 (s, 6H), 1.37 (s, 6H). ESI-MS (*m/z*): [M-H][−] calcd. 367.2, obsd. 367.3.

Compound 2-a and 2-b: **1** (110 mg, 0.3 mmol) and 4-acetamidobenzaldehyde (for compound **2-a**: 48.9 mg, 0.3 mmol; for compound **2-b**: 114.2 mg, 0.7 mmol) were dissolved in toluene (12 mL). Piperidine (0.32 mL) and acetic acid (0.2 mL) were added to the solution and refluxed overnight in a Dean-Stark apparatus (Reflux at 180 °C for compound **2-b** and at 140–160 °C for compound **2-a**). The solvent was evaporated under reduced pressure, and the residue was extracted with ethyl acetate. The combined organic layer was washed with water and dried over anhydrous Na₂SO₄. The product was concentrated by evaporation and purified by column chromatography on silica gel with DCM/MeOH (20/1 v/v to 10/1 v/v with 0.1 % acetic acid for compound **2-b**) or ethyl acetate/DCM (1/1 v/v with 0.2 % acetic acid for compound **2-a**) eluent, yielding **2-a** (22 mg, 14.3 %) and **2-b** (88 mg, 46.4%). **2-a**: ESI-MS (*m/z*): [M-H][−] calcd. 512.3, obsd. 512.3; **2-b**: ESI-MS (*m/z*): [M-H][−] calcd. 657.5, obsd. 657.3.

Compound 3: The azide formation was modified based on a previous report². Boc-Phe(4-NH₂)-OH (200 mg, 0.71 mmol) was dissolved in a mixture of water (1.4 mL) and THF (0.6 mL). HCl (12 M, 0.2 mL) was added at 4 °C, followed by NaNO₂ (74 mg, 1.07 mmol) in 0.6 mL of water. The mixture was stirred at this temperature for 30 min. NaN₃ (232 mg, 3.56 mmol) in water (0.6 mL) was then added. The stirring continued for another 30 min. The reaction mixture was extracted with CH₂Cl₂, dried over anhydrous Na₂SO₄, and concentrated to afford **3** (Yellow

product, 0.16 g, 84%). ¹H NMR (300 MHz, MeOH) δ 7.24 (d, *J* = 7.8 Hz, 2H), 6.95 (d, *J* = 7.8 Hz, 2H), 4.35 (dd, *J* = 8.0, 4.9 Hz, 1H), 3.14 (dd, *J* = 13.7, 4.6 Hz, 1H), 2.89 (dd, *J* = 13.5, 9.0 Hz, 1H), 1.38 (s, 9H). ESI-MS (*m/z*): [M+Na]⁺calcd. 329.1, obsd. 329.1.

Compound 4: **4** was synthesized based on our previous report³.

Compound 5: **4** (110 mg, 0.359 mmol) and HATU (273 mg, 0.719 mmol) was dissolved in 5 mL DCM, followed by the addition of DIEA (188 μL, 1.078 mmol) and **3** (115 mg, 0.377 mmol) in 10 mL DCM and 0.2 mL DMF. The reaction was left for 1–2 hrs. TLC (10% Methanol in DCM) was used to check the reaction. The reaction mixture was then diluted with DCM and extracted by 5% acetic acid and 10% NaHCO₃. The organic phase was dried by Na₂SO₄, filtered and rotary-evaporated to afford **5**. Flash chromatography (eluent: 3% methanol in DCM with 0.2% acetic acid) was used to purify the product (160 mg, 75%). ¹H NMR (300 MHz, CDCl₃) δ 7.17 (d, *J* = 8.1 Hz, 2H), 6.90 (d, *J* = 8.4 Hz, 2H), 5.40 (d, *J* = 8.3 Hz, 1H), 4.41 – 4.23 (m, 1H), 3.70 – 3.61 (m, 10H), 3.58 (s, 4H), 3.42 – 3.30 (m, 1H), 3.22 – 3.11 (m, 2H), 3.10 – 2.99 (m, 1H), 2.98 – 2.84 (m, 1H), 1.70 – 1.56 (m, 2H), 1.39 (s, 4H), 1.32 (s, 9H). ESI-MS (*m/z*): [M+H]⁺calcd. 615.3, obsd. 615.3.


Compound 6: **5** (50 mg, 0.102 mmol) was dissolved in 9 mL of DCM and 3 mL of TFA under stirring for about 1 hr. Then diethyl ether was added and all the solvent and TFA was blown away by condensed air to afford **6** (about 100% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.57 (s, 1H), 7.23 (d, *J* = 6.6 Hz, 2H), 6.97 (d, *J* = 7.3 Hz, 2H), 4.38 (s, 1H), 3.69 (s, 3H), 3.68 (s, 6H), 3.63 (s, 1H), 3.56 – 3.46 (m, 2H), 3.40 (s, 2H), 3.25 – 3.08 (m, 2H), 3.08 – 2.94 (m, 1H), 1.88 – 1.71 (m, 1H), 1.68 – 1.54 (m, 1H), 1.51 – 1.38 (m, 2H), 1.36 – 1.27 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 173.27, 172.68, 168.46, 139.53, 130.99, 119.38, 77.42, 77.10, 76.78, 64.18, 55.01, 52.88, 51.99, 51.59, 38.93, 36.84, 29.72, 29.40, 27.80, 22.33. ESI-MS (*m/z*): [M+H]⁺calcd. 493.2, obsd. 493.4.

Compound 7: A solution of **2-b** (29 mg, 0.044 mmol), EDC·HCl (67 mg, 0.35 mmol), HOBT (47.0 mg, 0.35 mmol), DIPEA (67 ml, 0.5 mmol, 10 molar equiv.), and **6** (53 mg, 0.087 mmol, 2.0 molar equiv.) was stirred in 1 mL DMF at room temperature under argon atmosphere. The reaction mixture was stirred for overnight until **2-b** was consumed. The reaction mixture was diluted with 50 mL DCM and washed with 10% NaHCO₃, water, 2% HCl and brine. The organic phase was collected, dried over anhydrous Na₂SO₄ and evaporated. The residue was purified by 3–5% MeOH in DCM with 0.2% acetic acid to afford **7** (35 mg, 70% yield). ¹H NMR (300 MHz, CDCl₃) δ 8.36 (s, 2H), 7.92 (d, *J* = 7.9 Hz, 2H), 7.60 – 7.48 (m, 6H), 7.48 – 7.39 (m, 4H), 7.32 (d, *J* = 7.8 Hz, 2H), 7.26 (d, *J* = 4.1 Hz, 2H), 7.16 (d, *J* = 16.1 Hz, 2H), 6.94 (d, *J* = 8.3 Hz, 2H), 6.80 – 6.69 (m, 1H), 6.61 (s, 2H), 4.96 (dd, *J* = 14.0, 7.0 Hz, 1H), 3.70 (d, *J* = 1.3 Hz, 9H), 3.65 – 3.49 (m, 5H), 3.40 (t, *J* = 7.6 Hz, 1H), 3.32 – 3.08 (m, 4H), 2.07 (s, 9H), 1.66 (dd, *J* = 6.2 Hz, 3H), 1.54 – 1.39 (m, 4H), 1.35 (s, 6H), 1.30 – 1.27 (m, 1H). ¹³C NMR (400 MHz, CDCl₃) δ 173.22, 172.12, 170.81, 168.99, 166.26, 153.02, 141.88, 139.26, 138.84, 138.70, 136.58, 134.52, 133.58, 132.91, 132.04, 130.91, 129.02, 128.42, 127.99, 119.82, 119.16, 118.26, 117.55, 77.40, 77.29, 77.09, 76.77, 64.21, 55.08, 52.65, 51.92, 51.61, 39.25, 38.49, 29.44, 28.01, 24.38, 22.73, 14.92, 14.18. ESI-MS (*m/z*): [M+Na]⁺calcd. 1155.5, obsd. 1155.3.

Reference

- (1) A. Singh, W. T. Yip and R. L. Halterman, *Org Lett*, 2012, **14**, 4046.

- (2) Y. S. Wang, X. Q. Fang, H.Y. Chen, B. Wu, Z. Y. U. Wang, C. Hilty and W. S. R. Liu, *ACS Chem Biol*, 2013, **8**, 405.
- (3) Y. T. Lai, Y. Y. Chang, L. G. Hu, Y. Yang, A. L. Chao, Z. Y. Du, J. A. Tanner, M. L. Chye, C. M. Qian, K. M. Ng, H. Y. Li and H. Sun, *Proc Natl Acad Sci USA*, 2015, **112**, 2948.



Scheme S1. Coupling of the photoactive cross-linker with NTA moiety.




Fig. S1. The normalized fluorescence changes of *NTA-AB* upon the addition of Ni^{2+} (as NiSO_4). The formation of Ni-NTA-AB accomplished within 40 min.




Fig. S2. The normalized excitation and emission spectra of *NTA-AB* (5 μ M) and *Ni-NTA-AB* (5 μ M). Both *NTA-AB* and *Ni-NTA-AB* exhibit the excitation wavelength of 570 nm and the emission wavelength of 590 nm.




Fig. S3. The fluorescence responses of *Ni-NTA-AB* for His-XPA122 addition over time. The samples were then subjected to UV irradiation at 365 nm for 10 min.




Fig. S4. Determination the detection limit of Ni-NTA-AB and quantification of the fluorescence protein bands in SDS-PAGE by ImageJ.




Fig. S5. Toxicity of Ni-NTA-AB in *E. coli* cells. Ni-NTA-AB (10 and 20 μM, with or without 0.25 % Tween 80) was incubated with *E. coli* cells. The toxicity was tested by counting the number of CFU after plating (n= 3).




Fig. S6. ESI-MS of *NTA-AB*. The ion at m/z 1089.3 corresponding to $[M-H]^-$ (cald. 1089.4). *Inset:* the pattern of isotopic distribution was identical to the simulation results.




Fig. S7. ESI-MS of *Ni-NTA-AB*. The ion at m/z 1146.9 corresponding to $[M-3H+Ni^{2+}]^-$ (cald. 1145.3). *Inset:* the pattern of isotopic distribution was identical to the simulation results.




Fig. S8. ¹H NMR spectrum of **3**.




Fig. S9. ¹H NMR spectrum of **4**.




Fig. S10. ^1H NMR spectrum of **5**.




Fig. S11. ^1H NMR spectrum of **6**.




Fig. S12. ¹H NMR spectrum of **1**.




Fig. S13. ¹H NMR spectrum of **7**.




Fig. S14. ^1H NMR spectrum of compound *NTA-AB* in deuterated methanol, water signal was suppressed.




Fig. S15. ^1H NMR spectrum of compound *NTA-AB* in deuterated DMSO.




Fig. S16. ^{13}C NMR spectrum of **6**.




Fig. S17. ^{13}C NMR DEPT spectrum of **6**.




Fig. S18. ^{13}C NMR spectrum of **7**.




Fig. S19. ^{13}C NMR DEPT spectrum of **7**.




Fig. S20. ^{13}C NMR spectrum of NTA-AB.




Fig. S21. ^{13}C NMR DEPT spectrum of *NTA-AB*.